FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Dilsher Dhoot, MD, shares 1 year results from the phase 2 ALTITUDE trial investigating RGX-314 gene therapy for the treatment of diabetic retinopathy.
According to Dhoot, the two dose levels of RGX-314 (Regenxbio, AbbVie) that were studied were well tolerated and demonstrated improvement in patient Diabetic Retinopathy Severity Scale score compared to a control group..
“I think the results of this trial are compelling,” he said. “Potentially having a one-time gene therapy in-office